Can BlackBerry (BBRY) Run Higher on Strong Earnings Estimate Revisions? – Tale of the Tape

Zacks

BlackBerry Limited (BBRY) is a wireless communications solutions provider company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BBRY’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that BlackBerry could be a solid choice for investors.

Current Quarter Estimates for BBRY

In the past 30 days, 13 estimates moved up for BlackBerry but there was no downward revision. The consensus estimate trend has been pretty favourable, with estimates narrowing to a loss of 18 cents a share from a loss of 28 cents, a significant move.

Current Year Estimates for BBRY

Meanwhile, BlackBerry s’ current year figures are also looking quite promising, with 12 estimates moving higher in the past month, compared to no downward revisions. The consensus estimate trend has also seen a boost for this time frame, narrowing from loss of $1.03 per share 30 days ago to loss of 63 cents per share today, a significant move.

Bottom Line

The stock has also started to move higher lately, adding 27% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 BlackBerry stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Be the first to comment

Leave a Reply